Madeline Robinson Slisz, PA-C

Madeline Slisz practices at General Physician in Buffalo, New York.

Madeline Slisz's NPI, 1659961076, was assigned on January 20, 2021.

Madeline Slisz's primary practice is General Physician, at 705 Maple Rd, Buffalo, NY 14221 in Erie County. The practice phone is (716) 692-3302.

Madeline Slisz's primary practice is General Physician in Buffalo, New York. The medical group on file is General Physician. Dmand AI also links Madeline Slisz to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Madeline Slisz practices, 3 sites in all. Vendor and product names are available with a free account.

Physician assistant is Madeline Slisz's primary specialty in the NPI Registry, under taxonomy code 363A00000X.

Dmand AI lists ADHD, alcohol use disorders, alzheimer's disease, anxiety, bipolar disorder, depression, drug use disorders and epilepsy among the conditions Madeline Slisz treats.

CMS data shows 886 Medicare services from Madeline Slisz across 3 procedure codes in 2024, for 239 Medicare patients. Medicare paid $64,780 for them.

CMS counts 239 Medicare patients who saw Madeline Slisz in 2024. The largest group is 85 and over, with 73 patients. 75% of them have high blood pressure, and 74% have mood disorders. 76% are also on Medicaid. Their average risk score is 2.56, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Madeline Slisz's median patient age at 79, with 67% women.

In 2024, Madeline Slisz wrote 2,878 Medicare Part D claims for 160 patients. 95% of them were for generic drugs. CMS names the drug for 2,807 of them, across 23 drugs with 11 or more claims each, at $110,753 in total drug cost.

Madeline Slisz accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 104 general payments to Madeline Slisz from 5 drug and device companies in 2025. Speaker and faculty fees make up the largest share, 72% of the total. Neurocrine BioSciences, Inc. paid the most, $26,285.